- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00092911
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
August 18, 2009 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder
The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
244
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatients
- Men and women age 18 years of age and older
- Women of childbearing potential participating in the study must have a negative serum pregnancy test result at screening and use a medically acceptable form of contraception
Exclusion Criteria:
- Treatment with DVS-233 SR at any time in the past
- Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1
- Known hypersensitivity to venlafaxine (IR or ER)
- Significant risk of suicide based on clinical judgment, including common
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Primary Completion (Actual)
May 1, 2005
Study Completion (Actual)
May 1, 2005
Study Registration Dates
First Submitted
September 24, 2004
First Submitted That Met QC Criteria
September 27, 2004
First Posted (Estimate)
September 28, 2004
Study Record Updates
Last Update Posted (Estimate)
August 19, 2009
Last Update Submitted That Met QC Criteria
August 18, 2009
Last Verified
August 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3151A1-320
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on DVS-233 SR
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedHot Flashes | Menopause | Sleep Disorders
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVasomotor SymptomsUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMenopauseBelgium, Finland, Sweden, South Africa, Croatia, United Kingdom, France, Romania, Ukraine, Spain, Poland, Hungary, Czech Republic, Mexico, Netherlands
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated